INTERCEPT Safety Evaluation on Whole Blood

Overview

The pathogen reduction system for whole blood using amustaline (S-303) and glutathione (GSH) hast a potential to decrease transfusion-transmitted infection. There is a scientific basis to hypothesize, that cells containing DNA and RNA such as bacteria, viruses and parasites that could be present in blood collected from asymptomatic infected donors are inactivated in the treated whole blood and therefore reduce the risk of transfusion-transmitted infections. The aim of the study is to assess the safety of whole blood treated with amustaline and glutathione and transfused in patients with anemia. This is a first-in-human-subjects study. Whole blood (WB) products treated with the amustaline (S-303) and glutathione (GSH) pathogen reduction technology have not been evaluated in human beings. However, red blood cells concentrates treated with amustaline and GSH have been evaluated in multiple clinical studies. The study described in this protocol is a randomized, controlled, open-label Phase I clinical trial. 20 patients will be randomized into either the Test or Control arm in a ratio of 1:1. 10 patients assigned to the Test arm will receive one amustaline/GSH treated whole blood product. 10 patients assigned to the Control arm will receive the Standard of Care (SOC), either one red blood cell (RBC) component or one whole blood product.

Screening: All potentially eligible patients at the participating institution will be approached for study consent prior to study transfusion. Enrolled patients will also be asked for consent to the storage of their samples for future research on Transfusion Transmitted Infections (TTI). Illiterate patients can be consented by an impartial witness (see section 2.7). Patients who consent to the study will be assigned a study identification (ID) number and undergo screening. Screening data collection and procedures will include: Demographics (age, sex), vital signs, height, weight, indication for anticipated transfusion, medical history including history of bleeding and transfusion and concomitant medications. A physical examination, including skin inspection, will be performed. Blood samples will be drawn for a hematological panel (including complete blood count, blood chemistry, blood type, coagulation (aPTT, PT and/or INR) and pregnancy test (if applicable). Immunohematology tests will be performed on a patient's sample at the blood center. This includes a Direct Antibody Test (DAT), immune reactivity to RBCs that have been processed with amustaline and glutathione, red cell alloantibody screen (Indirect Antibody Test (IAT) / Indirect Coombs). Blood samples (pre/post-treatment) for future research on TTIs will be archived in a biobank of the Institut Pasteur de Côte d'Ivoire (IPCI) (see section 9.3.3.11). Randomization: After successful screening, eligible patients will be assigned to a treatment arm by randomization. Randomization will be performed in the blood center by sequentially selecting a randomization envelope starting with the lowest number (e.g., 1 for the first eligible subject in ascending order up to envelope number 20 for the 20th subject). The ratio of patients assigned to the Test and Control group will be 1:1. Each subject will receive a Test product or an untreated product based on existing SOC. The assigned blood product number must be noted on the randomization assignment envelope and on the release form. The product number will also be entered into the case report form (CRF). The replacement strategy in this Phase I clinical trial is based on the aim to reach twenty evaluable patients. "Evaluable patients" is defined as those patients who are randomized and receive any study transfusion. If a randomized subject withdraws or is withdrawn from the study prior to the administration of any study transfusion, or does not receive any study transfusion through 7-days post-randomization, this subject will be replaced by the next eligible subject using the same randomization envelope. If a randomized subject receives a conventional (untreated) blood transfusion prior to study transfusion, the patient will be replaced as described above. All patients who received at least one investigational product will be included in the analysis (i.e., group of 20 evaluable patients) and followed through the final Day 58 study visit). All used and unused randomization envelopes will be kept in the Site File for reconciliation. Pre-transfusion visit: Vital signs, weight, skin inspection will be performed, hemoglobin will be assessed, and urine samples will be taken for detection of blood in urine. If the patient consents to future research on TTI, a sample will be drawn and sent to the archival biobank. Treatment: Patients will be transfused with one investigational product or SOC on Day 1. In case he or she requires further transfusion support to treat anemia, enrolled patients may be treated with a second study transfusion. A patient who requires a second blood component within the first 24 hours will receive a second treatment, if available, with an investigational product from the assigned treatment arm. This patient will be included into the analysis of evaluable patients and followed up to Day 58, the final study visit. If the patient requires further transfusions (third transfusion etc.) it will be SOC. Post-transfusion visit(s): Patients will be hospitalized for 24 hours after each study transfusion to allow close monitoring and data collection uniquely for the study purpose since their condition would allow an outpatient treatment. 3 hours and 6 hours after initiating each study transfusion vital signs and skin inspection will be performed. 24-hours post-transfusion vital signs, urine dipstick, concomitant medication/intervention will be assessed, laboratory blood samples for hemoglobin, coagulation assays (aPTT, PT and/or INR) and potassium and a sample for determination of residual S-300 will be taken. If a subject consented to future research on TTI, a second blood sample (post-transfusion) will be collected and archived in the biobank. In case clinical symptoms of transfusion-related bacterial contamination occur, a blood sample will be collected during the post-transfusion period and microbiological analysis will be performed according to standard procedures in the IPCI. Those patients will be treated according to SOC. Interim Safety Follow-up visit Day 14 days (+/-3 days) after last study transfusion: adverse event and and concomitant medication. Final Safety Follow-up visit Day 28 days (+/-3 days) after last study transfusion: At day 28 (+/-3 days) a physical examination, vitals, urine dipstick and blood samples will be collected for laboratory analysis of safety variables (e.g., complete blood count, coagulation) and urine dipstick. All Adverse Events (AE), Transfusion Reactions (TR) and unanticipated adverse device effects will be reviewed and recorded for the period from the first study transfusion through Day 28 after the last study transfusion. The Investigators will assess each AE for relation to the study transfusion. Available clinical diagnostic tools will be used to rule out unrelated AEs and to classify possible, probable and certain TRs using Swissmedic causality definitions. Final study visit on Day 58 (+/-7 days) after last study transfusion) At the final study visit, the immune reactivity of patient serum to RBCs treated with amustaline/GSH for patients in the test arm and a DAT test for all patients will be performed. Serious Adverse Events (SAEs) will be reviewed and recorded for the full study period from transfusion through to Day 28, which is the day of the final safety follow-up study visit. The Investigators will assess each SAE for relation to the study transfusion. As SAEs will be further evaluated as possible transfusion reactions. SAEs that are determined to be possibly, probably or certainly related to the transfusion will be classified as TRs.